Thursday, January 23, 2014
Publication and contact
spectroscopy (MRS) of hyperpolarized (2H,13C)-labeled
glucose to detect tumor response to drug treatment
Mouse studies suggest MRS
using a hyperpolarized (2H,13C)-labeled glucose probe
could help detect tumor responses to drug treatment. In mouse models of T
cell lymphoma and lung cancer, MRS using the probe detected the glycolysis
product (2H,13C)-labeled lactate in tumors within 15
seconds but not in normal tissues. In chemotherapy-treated mouse models of T
cell lymphoma, MRS using the probe showed that the intratumoral ratio of
lactate to glucose signals decreased by 62% 24 hours after treatment compared
with no treatment. Planned work includes comparing the sensitivity of the
method and 18F-labeled fluorodeoxyglucose PET imaging in tumor
Published online Jan. 23, 2014
Rodrigues, T.B. et al.
Nat. Med.; published online Dec. 8, 2013;
Contact: Kevin M. Brindle, University of Cambridge,
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]